Jon Congleton
Known title: Chief Executive OfficerCIK: 0001644975
Jon Congleton's purchase track record
How the stock did after each of Jon Congleton's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 11, 2023
Stock higher 6 months later
100%
3 months: 33%
Median 6-month return
+15.5%
3 months: -46.1%
Beat the S&P 500
100%
median +2.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2023 | MLYS | $25K | +155.9% | +110.1% | +16.5% |
| 9/6/2023 | MLYS | $27K | -46.1% | +15.5% | +14.3% |
| 8/11/2023 | MLYS | $53K | -49.6% | +15.0% | +12.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MLYS | ▼ Sell | Open Market | 75,000 | $1.9M | 9/30/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,700 | $291K | 7/13/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 58,000 | $1.5M | 6/30/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 17,000 | $456K | 6/30/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 15,730 | $422K | 4/13/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 55,183 | $1.5M | 3/31/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 453 | $12K | 3/31/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 19,364 | $494K | 3/31/2026 | View on chart |
| MLYS | ▲ Buy | Grant | 140,900 | $0 | 2/19/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 9,119 | $294K | 1/12/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 7,117 | $236K | 1/12/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 24,082 | $13K | 11/21/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 12,806 | $533K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 8,862 | $375K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 112,275 | $5.1M | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 4,000 | $174K | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 29,207 | $1.3M | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 32,850 | $1.5M | 11/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 13,548 | $578K | 10/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 1,552 | $67K | 10/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 15,884 | $230K | 7/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 15,319 | $187K | 4/11/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 18,333 | $166K | 1/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 15,271 | $206K | 10/11/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 15,746 | $210K | 7/11/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 14,940 | $175K | 6/20/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 16,607 | $199K | 6/18/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 17,766 | $218K | 6/17/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 16,229 | $203K | 6/14/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 39,961 | $509K | 6/13/2024 | View on chart |
| MLYS | ▼ Sell | Open Market | 16,607 | $212K | 6/12/2024 | View on chart |
| MLYS | ▲ Buy | Open Market | 4,250 | $25K | 11/22/2023 | View on chart |
| MLYS | ▲ Buy | Open Market | 2,250 | $27K | 9/6/2023 | View on chart |
| MLYS | ▲ Buy | Open Market | 2,250 | $27K | 8/17/2023 | View on chart |
| MLYS | ▲ Buy | Open Market | 2,000 | $26K | 8/11/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.